Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
11 pending office actions • 4 art units • 10 examiners • 0 of 11 (0%) have an AI response strategy ready • 14 patents granted in the last 365 days
Codexis Inc. manages a portfolio in the Biotechnology & Pharmaceuticals technology area, currently facing 12 pending office actions. These actions are distributed among 11 distinct examiners and across 5 distinct art units. This suggests a broad range of active matters requiring coordination across multiple technical groups within the patent office. The high number of distinct examiners relative to the total actions indicates that the company's prosecution is not concentrated under a few individuals.
MOHAMMAD Y MEAH is the busiest examiner for the company, handling 2 pending office actions. The remaining actions are spread across the other distinct examiners, indicating that most examiners are managing individual matters for the company. With 12 pending office actions and 5 distinct art units, the portfolio shows substantial activity and diversity in its examination path. Practitioners should be prepared for a variety of examiner styles given the high count of 11 distinct examiners involved.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (27%) |
| §112 only | 1 (9%) |
| Double-patenting only | 1 (9%) |
| Double-patenting + other | 4 (36%) |
| Multi-statute (no §101) | 1 (9%) |
| No statute on record | 1 (9%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MEAH, MOHAMMAD Y | 2 | 70.8% | +42.7% |
| EPSTEIN, TODD MATTHEW | 1 | 60.9% | +43.4% |
| HOLLAND, PAUL J | 1 | 57.5% | +64.6% |
| BOWERS, ERIN M | 1 | 54.7% | +10.6% |
| HUTSON, RICHARD G | 1 | 65.1% | +53.1% |
| ROBINSON, HOPE A | 1 | 67.7% | +43.1% |
| GRAY, JESSICA | 1 | 0.0% | +0.0% |
| MCKNIGHT, CIARA A | 1 | 60.8% | +38.8% |
| JONES-FOSTER, ERICA NICOLE | 1 | 48.1% | +44.7% |
| NOAKES, SUZANNE MARIE | 1 | 73.3% | +18.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18516054 | P450-BM3 VARIANTS WITH IMPROVED ACTIVITY | MCKNIGHT, CIARA A | 34d |
| 18660851 | RNA POLYMERASE VARIANTS | BOWERS, ERIN M | — |
| 18661523 | ENGINEERED RNA POLYMERASE VARIANTS | HUTSON, RICHARD G | — |
| 18395294 | ENGINEERED RNA LIGASE VARIANTS | GRAY, JESSICA | — |
| 18485925 | ENGINEERED 3-O-KINASE VARIANTS AND METHODS OF USE | NOAKES, SUZANNE MARIE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18516054 | P450-BM3 VARIANTS WITH IMPROVED ACTIVITY | MCKNIGHT, CIARA A | 34d |
| 18971755 | BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF SUBSTITUTED LACTAMS | EPSTEIN, TODD MATTHEW | — |
| 18886292 | BIOCATALYSTS FOR EZETIMIBE SYNTHESIS | MEAH, MOHAMMAD Y | — |
| 18822990 | ENGINEERED PANTOTHENATE KINASE VARIANT ENZYMES | HOLLAND, PAUL J | — |
| 18781007 | LOV-D ACYLTRANSFERASE MEDIATED ACYLATION | MEAH, MOHAMMAD Y | — |
| 18660851 | RNA POLYMERASE VARIANTS | BOWERS, ERIN M | — |
| 18661523 | ENGINEERED RNA POLYMERASE VARIANTS | HUTSON, RICHARD G | — |
| 18638060 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | ROBINSON, HOPE A | — |
| Art Unit | Apps |
|---|---|
| 1656 | 3 |
| 1652 | 2 |
| 1653 | 1 |
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18971755 | BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF SUBSTITUTED LACTAMS | EPSTEIN, TODD MATTHEW | — | Other | Non-Final OA | — | Pending | Dec 06, 2024 |
| 18886292 | BIOCATALYSTS FOR EZETIMIBE SYNTHESIS | MEAH, MOHAMMAD Y | — | §112DP | Non-Final OA | — | Pending | Sep 16, 2024 |
| 18822990 | ENGINEERED PANTOTHENATE KINASE VARIANT ENZYMES | HOLLAND, PAUL J | — | §112DP | Non-Final OA | — | Pending | Sep 03, 2024 |
| 18781007 | LOV-D ACYLTRANSFERASE MEDIATED ACYLATION | MEAH, MOHAMMAD Y | — | DP | Non-Final OA | — | Pending | Jul 23, 2024 |
| 18660851 | RNA POLYMERASE VARIANTS | BOWERS, ERIN M | 1653 | §101§102 | Non-Final OA | — | Pending | May 10, 2024 |
| 18661523 | ENGINEERED RNA POLYMERASE VARIANTS | HUTSON, RICHARD G | 1652 | §101§102§103§112 | Non-Final OA | — | Pending | May 10, 2024 |
| 18638060 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | ROBINSON, HOPE A | 1652 | §112 | Non-Final OA | — | Pending | Apr 17, 2024 |
| 18395294 | ENGINEERED RNA LIGASE VARIANTS | GRAY, JESSICA | 1682 | §102§103DP | Non-Final OA | — | Pending | Dec 22, 2023 |
| 18516054 | P450-BM3 VARIANTS WITH IMPROVED ACTIVITY | MCKNIGHT, CIARA A | 1656 | §102§103Other | Non-Final OA | 34d | Pending | Nov 21, 2023 |
| 18516310 | P450-BM3 VARIANTS WITH IMPROVED ACTIVITY | JONES-FOSTER, ERICA NICOLE | 1656 | §102§103§112DP | Non-Final OA | — | Pending | Nov 21, 2023 |
| 18485925 | ENGINEERED 3-O-KINASE VARIANTS AND METHODS OF USE | NOAKES, SUZANNE MARIE | 1656 | §101§102DP | Final Rejection | — | Pending | Oct 12, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial